Prime Highlights-
- Daiichi Sankyo aims to generate over 2.3 trillion yen in oncology revenue by 2030 through new cancer drug launches.
- The company plans to become a global top five oncology company by 2035 by expanding innovation and research capabilities.
Key Facts-
- Daiichi Sankyo is a global healthcare company focused on oncology and advanced drug development technologies.
- The company plans to launch more than 20 new indications across five medicines under its latest five-year business roadmap.
Background-
Daiichi Sankyo has announced a new five-year business plan focused on expanding its oncology business and strengthening its position in the global pharmaceutical market. The company said it aims to generate more than 2.3 trillion yen in oncology revenue by 2030 and become one of the world’s top five oncology companies by 2035.
The strategy centres on the expansion of the company’s antibody drug conjugate portfolio and the launch of more than 20 new indications across five medicines. The company expects these treatments to reach over 700,000 new patients annually by 2035.
During fiscal year 2026, Daiichi Sankyo plans several new launches across different global markets, including additional breast cancer treatments linked to Enhertu and Datroway, along with its first launch in small cell lung cancer.
President and CEO Hiroyuki Okuzawa said the company was entering a transformative phase and planned to use its scientific and technological strengths to deliver innovative medicines more quickly while supporting long-term growth.
The company also plans to expand research in new technologies, including multi-specific antibodies, targeted protein degradation and siRNA-based medicines. It said artificial intelligence and digital tools would be used to improve clinical development and operational efficiency.
Daiichi Sankyo added that it is targeting stronger profitability, wider use of renewable energy and lower carbon emissions as part of its long-term growth strategy.
